Guidance
Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions for people with early breast cancer. The tests are EndoPredict (EPclin score), Oncotype DX Breast Recurrence Score, Prosigna, MammaPrint and IHC4+C.
Is this guidance up to date?
Next review: 2021
Commercial arrangements
There is an access proposal for EndoPredict. Contact NHS_EndoPredict@myriad.com or 020 3897 6620 or 6621 for details.
There is an access proposal for Oncotype DX. Contact SOgram@genomichealth.com or 020 3031 8087 for details.
There is an access proposal for Prosigna. Contact prosigna_uk@nanostring.com or 01494 590430 for details.
Guidance development process
How we develop NICE diagnostics guidance
This guidance replaces NICE diagnostics guidance on gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10). It also replaces NICE medtech innovation briefings on Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence (MIB27) and EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44).